EVALUATION OF A NOVEL FLUORESCENCE POLARIZATION IMMUNOASSAY FOR TEICOPLANIN

被引:16
作者
COX, H
WHITBY, M
NIMMO, G
WILLIAMS, G
机构
[1] UNIV QUEENSLAND,DEPT INFECT DIS,BRISBANE,QLD 4000,AUSTRALIA
[2] UNIV QUEENSLAND,DEPT MICROBIOL,BRISBANE,QLD 4000,AUSTRALIA
[3] UNIV QUEENSLAND,PRINCESS ALEXANDRA HOSP,BRISBANE,QLD 4000,AUSTRALIA
[4] UNIV QUEENSLAND,MPH PROGRAM,BRISBANE,QLD 4000,AUSTRALIA
关键词
D O I
10.1128/AAC.37.9.1924
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A fluorescence polarization immunoassay (FPI) for teicoplanin that uses the TDx Instrument System (Abbott, Irving, Tex.) as an automated analyzer has been developed by Innotron of Oregon Inc. and was evaluated in patients with staphylococcal infections enrolled in a clinical trial of the antibiotic. The assay proved accurate in estimating concentrations of between 5 and 100 mg/liter. The intraassay coefficient of variation was <7.3%, while the interassay variance was <11.6% against three commercially prepared standards at known concentrations of approximately 5, 35, and 75 mg/liter. Against routinely prepared standards at 10 concentrations between 5 and 100 mg/liter analyzed in a single run, the coefficient of variance did not exceed 4.3%. Compared with bioassay, the FPI demonstrated good correlation in terms of reliability (r = 0.909) in samples containing teicoplanin only and specificity (r = 0.916) in samples containing both teicoplanin and gentamicin. With a turnaround time of 20 min and with only 50 mul of serum needed for estimation of the amount of drug in a sample, the FPI described here should provide a useful method of teicoplanin measurement in routine diagnostic laboratories.
引用
收藏
页码:1924 / 1926
页数:3
相关论文
共 9 条
[1]   PROSPECTIVE RANDOMIZED CLINICAL-TRIAL OF TEICOPLANIN FOR EMPIRIC COMBINED ANTIBIOTIC-THERAPY IN FEBRILE, GRANULOCYTOPENIC ACUTE-LEUKEMIA PATIENTS [J].
DELFAVERO, A ;
MENICHETTI, F ;
GUERCIOLINI, R ;
BUCANEVE, G ;
BALDELLI, F ;
AVERSA, F ;
TERENZI, A ;
DAVIS, S ;
PAULUZZI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1126-1129
[2]   A SENSITIVE BIOASSAY FOR TEICOPLANIN IN SERUM IN THE PRESENCE OR ABSENCE OF OTHER ANTIBIOTICS [J].
ERICKSON, RC ;
HILDEBRAND, AR ;
HOFFMAN, PF ;
GIBSON, CB .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1989, 12 (03) :235-241
[3]  
Fuller W.A., 2009, MEASUREMENT ERROR MO, V305, DOI DOI 10.1002/9780470316665
[4]  
PATTON KR, 1987, DRUG EXP CLIN RES, V13, P547
[5]   TEICOPLANIN PHARMACOKINETICS IN INTRAVENOUS DRUG-ABUSERS BEING TREATED FOR BACTERIAL-ENDOCARDITIS [J].
RYBAK, MJ ;
LERNER, SA ;
LEVINE, DP ;
ALBRECHT, LM ;
MCNEIL, PL ;
THOMPSON, GA ;
KENNY, MT ;
YUH, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :696-700
[6]   CLINICAL-EVALUATION OF TEICOPLANIN FLUORESCENCE POLARIZATION IMMUNOASSAY [J].
RYBAK, MJ ;
BAILEY, EM ;
REDDY, VN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (08) :1586-1590
[7]   SIMPLE METHOD FOR ELIMINATION OF AMINOGLYCOSIDES FROM SERUM TO PERMIT BIOASSAY OF OTHER ANTIMICROBIAL AGENTS [J].
STEVENS, P ;
YOUNG, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1977, 12 (02) :286-287
[8]   RANDOMIZED STUDY OF VANCOMYCIN VERSUS TEICOPLANIN FOR THE TREATMENT OF GRAM-POSITIVE BACTERIAL-INFECTIONS IN IMMUNOCOMPROMISED HOSTS [J].
VANDERAUWERA, P ;
AOUN, M ;
MEUNIER, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :451-457
[9]  
1988, SAS STAT USERS GUIDE